The cytokine storm which follows joint bleeding: identifying a plasma signature of joint bleeding
The cytokine storm which follows joint bleeding: relationship of plasma cytokine concentrations and joint tissue gene expression in acute stage of hemarthrosis
Association of Overweight and Obesity with the Use of Self and Home-Based Infusion Therapy
Characteristics and Treatment Patterns of Medicaid Patients with Hemophilia A Receiving Prophylaxis vs. On-Demand Factor VIII Therapy
Objective: Few data sources contain sufficient patient count to study the real-world efficacy of factor VIII (FVIII) therapy in patients with hemophilia A (HA). Health insurance claims databases offer that opportunity. This study…
Low inhibitor incidence in previously untreated patients with severe haemophilia A treated with octanate® - Update from the PUP-GCP clinical trial
Background: Octanate is a highly purified, double virus inactivated, human plasma-derived factor VIII (FVIII) concentrate with all coagulation FVIII bound to its natural stabilizer VWF in a VWF:RCo/FVIII:C ratio of approximately…
Assuring the Virus Safety of Source Plasma for Further Manufacturing by Establishing Epidemiological Limits in Donor Centers
Pathogen Safety of Plasma-Derived Clotting Factor Concentrates Demonstrated by Validation of Inactivation and Removal Steps in the Manufacturing Process
Objective: To assure plasma-derived clotting factor concentrates are pathogen safe, virus inactivation and removal methods are applied to the manufacturing process. The effectiveness of currently used methods and procedures was…
Patients’ and Caregivers’ Perspectives on Stability of Factor VIII Products for Hemophilia A: A Web-Based Study in the United States and Canada
Global Development Plan for a Double Virus Inactivated Fibrinogen Concentrate for the Treatment of Congenital Fibrinogen Deficiency
Use of a double virally inactivated FVIII/VWF in 30 children and young people with von Willebrands disease - a single centre experience